Vericella Zoaster DNA BY PCR

The Vericella Zoaster DNA BY PCR test is a molecular diagnostic that detects Varicella‑Zoster Virus (VZV) DNA using polymerase chain reaction (PCR) from clinical specimens. By amplifying viral genetic material, the test provides highly sensitive and specific evidence of active VZV infection, useful for distinguishing chickenpox (varicella) and shingles (herpes zoster) from other vesicular or rash‑causing conditions.

This service includes professional home sample collection across Dubai and the UAE followed by laboratory PCR analysis and reporting, enabling prompt clinical decisions and initiation of antiviral therapy when indicated. Results are reported with interpretive comments and laboratory parameters (such as Ct value and viral load when applicable); clinical correlation with patient history and physician consultation is recommended for management and follow‑up.

• Varicella‑Zoster Virus (VZV) DNA — Qualitative detection
• VZV DNA Viral Load (Quantitative), if requested
• Cycle Threshold (Ct) value
• Specimen type identification (vesicular swab / lesion scraping / CSF)
• Internal PCR amplification control

• Acute vesicular rash suspicious for chickenpox or shingles
• Atypical, severe, or disseminated rash in adults
• Immunocompromised patients with suspected VZV exposure or symptoms
• Neurological symptoms suggesting VZV meningitis or encephalitis
• Neonates or pregnant women with potential VZV exposure
• When rapid confirmation is needed to guide antiviral therapy

• High sensitivity and specificity for active VZV infection
• Home sample collection across Dubai and the UAE for patient convenience
• Rapid laboratory turnaround to support timely treatment decisions
• Quantitative reporting (viral load/Ct) when available to aid clinical interpretation
• Reduces need for empiric treatment uncertainty and unnecessary additional testing

• Preferred specimen: vesicular lesion swab or lesion scraping; CSF for suspected CNS involvement
• Do not apply topical creams or antiseptics to lesions before sampling
• Inform the collector if antiviral therapy (e.g., acyclovir) has already been started
• Provide valid UAE ID and brief clinical history at time of home collection